Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 19/20 | 0.41 |
| ▸ | KDR | P35968 | 4/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30071117 | 1.00 | RET (0.41) | RETKDRRXFP1 | |
| SCHEMBL24464378 | 0.82 | RET (0.41) | RETKDRRXFP1 | |
| SCHEMBL1482339 | 0.81 | RET (0.53) | RETKDR | |
| SCHEMBL29897212 | 0.81 | RET (0.53) | RETKDR | |
| SCHEMBL24429585 | 0.81 | RET (0.43) | RETKDRRXFP1 | |
| SCHEMBL29897206 | 0.78 | RET (0.39) | RETKDRRXFP1 | |
| SCHEMBL21179100 | 0.78 | RET (0.39) | RETKDRRXFP1 | |
| SCHEMBL30566171 | 0.78 | RXFP1 (0.39) | RXFP1 | |
| SCHEMBL13966385 | 0.78 | RXFP1 (0.39) | RXFP1 | |
| SCHEMBL21179014 | 0.77 | RET (0.39) | RETKDRRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236624-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2025-07-24 | — | — | US | disclosed |
| US-20250115598-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2025-04-10 | — | — | US | disclosed |
| US-20250059188-A1 | ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2025-02-20 | — | — | US | disclosed |
| EP-4452977-A1 | ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2024-10-30 | — | — | EP | disclosed |
| EP-4452978-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2024-10-30 | — | — | EP | disclosed |
| US-20240116938-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-04-11 | — | — | US | disclosed |
| US-20230339954-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-10-26 | — | — | US | disclosed |
| US-20230339954-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-10-26 | — | — | US | disclosed |
| US-20230339954-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-10-26 | — | — | US | disclosed |
| WO-2023115142-A1 | ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| WO-2017178844-A1 | HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-10-19 | — | — | WO | disclosed |
| WO-2017178845-A1 | HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-10-19 | — | — | WO | disclosed |
| WO-2017178845-A1 | HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-10-19 | — | — | WO | disclosed |
| US-8637542-B2 | Kinase inhibitors and methods of use | INTELLIKINE, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637542-B2 | Kinase inhibitors and methods of use | INTELLIKINE, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637542-B2 | Kinase inhibitors and methods of use | INTELLIKINE, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20110077268-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-03-31 | — | — | US | disclosed |
| US-20110077268-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-03-31 | — | — | US | disclosed |
| US-20110077268-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-03-31 | — | — | US | disclosed |
| WO-2009114870-A2 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE, INC. (US) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115598-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | MLKL, CASP1, CASP9 | RET 1795/4885KDR 2442/4885RXFP1 2827/4885 |
| US-20250236624-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | RET, REL, BCR | RET 1/4885KDR 400/4885RXFP1 560/4885 |
| US-20110077268-A1 | KINASE INHIBITORS AND METHODS OF USE | MAP3K20, MAP3K1, PDPK1 | RET 443/4885KDR 931/4885RXFP1 4537/4885 |
| US-20230339954-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | RET, REL, BCR | RET 1/4885KDR 400/4885RXFP1 560/4885 |
| US-20240116938-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | RET, HIPK4, HIPK3 | RET 1/4885KDR 793/4885RXFP1 628/4885 |
| US-20250059188-A1 | ARYLSULPHONAMIDE COMPOUNDS | MLKL, CASP1, CASP9 | RET 1406/4885KDR 1698/4885RXFP1 2812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.